Novartis to move UK headquarters to London in bold move to join emerging life sciences cluster
Nov 28, 2018
Novartis is to move its UK headquarters to The WestWorks building on the White City Place campus, which is emerging as London’s latest life sciences cluster
The new Novartis UK office will be fully operational by the beginning of 2020
As a medicines company powered by data and digital, Novartis will be at the heart of this important innovation hub
Frimley, 28th November 2018 – Novartis today announced it will move its UK headquarters to London, in a multi-million pound investment in UK life sciences. The company will relocate to The WestWorks, White City by January 2020.
The WestWorks, located on the 1.9 million sq ft campus in White City Place, is home to a number of exciting technology and innovation companies. White City Place is emerging to be London’s latest life sciences cluster. It is quickly becoming home to a number of pioneering life sciences companies at the forefront of innovation, as well as Imperial College London’s major new research and innovation campus at White City. The campus co-locates multidisciplinary research with global businesses, new start-ups and fast-growth technology companies on an unprecedented scale.
“The nature of healthcare and medicine is changing and as we pivot towards becoming a focused medicines company, powered by digital and data, we want to be closer to our customers and partners, and become better networked in the healthcare and life science ecosystem.” said Haseeb Ahmad, Novartis UK Country President. “White City is quickly becoming one of the UK’s life sciences and technology districts, and the ethos of The WestWorks campus complements how we work to deliver on our strategy to reimagine medicine.”
“At Imperial, we firmly believe that the co-location of academic research and businesses is central to driving innovation and economic growth. This is at the heart of our vision for White City. Novartis is a natural fit for White City’s booming life sciences ecosystem, and we hope that this move will pave the way to new collaborations and partnerships to enhance our work in this area” said Professor David Gann, Vice President (Innovation) at Imperial College London.
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic and biosimilar pharmaceuticals and eye care. Novartis has leading positions globally in each of these areas. In 2017, the Group achieved net sales of USD 49.1 billion, while R&D throughout the Group amounted to approximately USD 9.0 billion. Novartis Group companies employ approximately 125,000 full-time-equivalent associates. Novartis products are sold in approximately 155 countries around the world. For more information, please visit http://www.novartis.com.
In the UK, we employ approximately 1,500 people to serve healthcare needs across the whole of the UK, as well as supporting the global operations of Novartis. In 2017 Novartis invested almost £30million in R&D and is a leading sponsor of clinical trials in the UK. For more information, please visit www.novartis.co.uk.